{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T16:48:42Z","timestamp":1754153322522,"version":"3.41.2"},"reference-count":23,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1136\/ijgc-2021-003009","type":"journal-article","created":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T12:35:16Z","timestamp":1648038916000},"page":"906-912","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Treatment patterns after poly-ADP ribose polymerase (PARP) inhibitors in epithelial ovarian cancer patients"],"prefix":"10.1016","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9738-1580","authenticated-orcid":false,"given":"Tharani","family":"Sivakumaran","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Krasovitsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alison","family":"Freimund","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yeh Chen","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kate","family":"Webber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jane","family":"So","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christie","family":"Norris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Friedlander","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda","family":"Mileshkin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George","family":"Au-Yeung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1136\/ijgc-2021-003009_bb0010","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1038\/s41571-018-0055-6","article-title":"Synthetic lethal therapies for cancer: what's next after PARP inhibitors?","volume":"15","author":"Ashworth","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1136\/ijgc-2021-003009_bb0015","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer","volume":"379","author":"Moore","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1136\/ijgc-2021-003009_bb0020","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S1470-2045(17)30469-2","article-title":"Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"18","author":"Pujade-Lauraine","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1136\/ijgc-2021-003009_bb0025","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","article-title":"Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer","volume":"375","author":"Mirza","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1136\/ijgc-2021-003009_bb0030","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(17)32440-6","article-title":"Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"Coleman","year":"2017","journal-title":"Lancet"},{"key":"10.1136\/ijgc-2021-003009_bb0035","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.15_suppl.6002","article-title":"Final overall survival (OS) results from SOLO2\/ENGOT-ov21: a phase III trial assessing maintenance olaparib in patients (PTS) with platinum-sensitive, relapsed ovarian cancer and a BRCA mutation","volume":"38","author":"Poveda","year":"2020","journal-title":"JCO"},{"key":"10.1136\/ijgc-2021-003009_bb0040","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.ygyno.2015.12.020","article-title":"Efficacy and safety of olaparib monotherapy in germline BRCA1\/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy","volume":"140","author":"Domchek","year":"2016","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2021-003009_bb0045","doi-asserted-by":"crossref","first-page":"4371","DOI":"10.2147\/CMAR.S200524","article-title":"Current status and future prospects of PARP inhibitor clinical trials in ovarian cancer","volume":"11","author":"Jiang","year":"2019","journal-title":"Cancer Manag Res"},{"key":"10.1136\/ijgc-2021-003009_bb0050","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/j.tcb.2019.07.008","article-title":"Parp inhibitor resistance: a tug-of-war in BRCA-Mutated cells","volume":"29","author":"Noordermeer","year":"2019","journal-title":"Trends Cell Biol"},{"key":"10.1136\/ijgc-2021-003009_bb0055","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-019-09312-9","article-title":"Multiple ABCB1 transcriptional fusions in drug resistant high-grade serous ovarian and breast cancer","volume":"10","author":"Christie","year":"2019","journal-title":"Nat Commun"},{"key":"10.1136\/ijgc-2021-003009_bb0060","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/j.hoc.2018.07.007","article-title":"Mechanisms of drug resistance in high-grade serous ovarian cancer","volume":"32","author":"Freimund","year":"2018","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1136\/ijgc-2021-003009_bb0065","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/s12276-021-00557-3","article-title":"Alternate therapeutic pathways for PARP inhibitors and potential mechanisms of resistance","volume":"53","author":"Kim","year":"2021","journal-title":"Exp Mol Med"},{"key":"10.1136\/ijgc-2021-003009_bb0070","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.5563","article-title":"Outcomes of ovarian cancer patients treated with platinum or non-platinum based chemotherapy after PARP inhibitor maintenance","volume":"39","author":"Brann","year":"2021","journal-title":"JCO"},{"key":"10.1136\/ijgc-2021-003009_bb0075","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.15_suppl.6070","article-title":"Patterns of progression and subsequent management of patients with BRCA1\/2 mutated platinum-sensitive recurrent epithelial ovarian cancer (EOC) progressing on olaparib versus placebo: the SOLO2\/ENGOT Ov-21 trial","volume":"38","author":"Frenel","year":"2020","journal-title":"JCO"},{"key":"10.1136\/ijgc-2021-003009_bb0080","doi-asserted-by":"crossref","first-page":"5485","DOI":"10.1158\/1078-0432.CCR-13-1262","article-title":"Efficacy of chemotherapy in BRCA1\/2 mutation carrier ovarian cancer in the setting of PARP inhibitor resistance: a multi-institutional study","volume":"19","author":"Ang","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1136\/ijgc-2021-003009_bb0085","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.annonc.2020.02.008","article-title":"Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1\/2-mutant metastatic breast cancer","volume":"31","author":"Waks","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1136\/ijgc-2021-003009_bb0090","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.celrep.2015.12.046","article-title":"Platinum and PARP inhibitor resistance due to overexpression of MicroRNA-622 in BRCA1-Mutant ovarian cancer","volume":"14","author":"Choi","year":"2016","journal-title":"Cell Rep"},{"key":"10.1136\/ijgc-2021-003009_bb0095","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1093\/annonc\/mdy099","article-title":"RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer","volume":"29","author":"Cruz","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1136\/ijgc-2021-003009_bb0100","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-018-03917-2","article-title":"Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance","volume":"9","author":"Pettitt","year":"2018","journal-title":"Nat Commun"},{"key":"10.1136\/ijgc-2021-003009_bb0105","doi-asserted-by":"crossref","first-page":"6084","DOI":"10.1158\/0008-5472.CAN-15-3240","article-title":"The PARP inhibitor AZD2461 provides insights into the role of PARP3 inhibition for both synthetic lethality and tolerability with chemotherapy in preclinical models","volume":"76","author":"Oplustil O'Connor","year":"2016","journal-title":"Cancer Res"},{"key":"10.1136\/ijgc-2021-003009_bb0110","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/j.ccell.2018.05.008","article-title":"Selective loss of PARG restores PARylation and counteracts PARP inhibitor-mediated synthetic lethality","volume":"33","author":"Gogola","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1136\/ijgc-2021-003009_bb0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100135","article-title":"Recurrent ovarian cancer in the era of poly-ADP ribose polymerase inhibitors: time to re-assess established clinical practices","volume":"6","author":"Bartoletti","year":"2021","journal-title":"ESMO Open"},{"key":"10.1136\/ijgc-2021-003009_bb0120","first-page":"S1283","article-title":"Maintenance olaparib rechallenge in patients (PTS) with ovarian carcinoma (OC) previously treated with a PARP inhibitor: phase IIIB OReO\/ENGOT Ov-38 trial","volume":"32","author":"Puiade-Lauraine","year":"2021","journal-title":"Annals of Oncology"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24007801?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24007801?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ijgc-2021-003009","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T22:39:41Z","timestamp":1753223981000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X24007801"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":23,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["S1048891X24007801"],"URL":"https:\/\/doi.org\/10.1136\/ijgc-2021-003009","relation":{},"ISSN":["1048-891X"],"issn-type":[{"type":"print","value":"1048-891X"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment patterns after poly-ADP ribose polymerase (PARP) inhibitors in epithelial ovarian cancer patients","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ijgc-2021-003009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2022 IGCS and ESGO 2022. No commercial re-use. See rights and permissions. Published by BMJ.","name":"copyright","label":"Copyright"}]}}